Table 2.
Bridging therapies.
| 2-day LDC Regimen (n=64); N (%) |
3-day LDC Regimen (n=28); N (%) |
All Patients (n=92); N (%) |
|
|---|---|---|---|
| None | 18 (28) | 17 (61) | 35 (38) |
| Any Bridging | 46 (72) | 11 (39) | 57 (42) |
| Radiation | 8 (12.5) | 5 (18) | 13 (14) |
| Platinum regimens* |
10 (15.6) | 4 (20) | 13 (14) |
| Polatuzumab +Rituximab** |
20 (31.2) | 0 | 20 (22) |
| Glucocorticoids | 4 (6.3) | 1 (4) | 5 (5.4) |
| Other | 4 (6.3) | 1 (4) | 6 (6.5) |
*Platinum containing regimens: rituximab/ifosfamide/carboplatin/etoposide; rituximab/gemcitabine/oxaliplatin; rituximab/dexamethasone/cytarabine/cisplatin; rituximab/dexamethasone/cytarabine/oxaliplatin.
** +/- Bendamustine.
LDC: lymphodepleting chemotherapy.